LEK-8822

LEK-8822
Clinical data
Other namesLEK8822; 9,10-Dihydro-LEK-8842; 9,10-Dihydro-N-methyl-N-(2-propynyl)lysergamide; N-Methyl-N-(2-propynyl)-6-methylergoline-8β-carboxamide
Drug classMonoamine receptor modulator
ATC code
  • None
Identifiers
  • (6aR,9R,10aR)-N,7-dimethyl-N-prop-2-ynyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChem CID
Chemical and physical data
FormulaC20H23N3O
Molar mass321.424 g·mol−1
3D model (JSmol)
  • CN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)N(C)CC#C
  • InChI=1S/C20H23N3O/c1-4-8-22(2)20(24)14-9-16-15-6-5-7-17-19(15)13(11-21-17)10-18(16)23(3)12-14/h1,5-7,11,14,16,18,21H,8-10,12H2,2-3H3/t14-,16-,18-/m1/s1
  • Key:ZAVOMKKGYAVBPY-QGPMSJSTSA-N

LEK-8822, also known as 9,10-dihydro-LEK-8842 or as 9,10-dihydro-N-methyl-N-(2-propynyl)lysergamide, is a monoamine receptor modulator of the lysergamide family related to 9,10-dihydro-LSD.[1] It is the analogue of LEK-8842 in which the double bond between the 9 and 10 positions of the ergoline ring system has been dihydrogenated.[1] The drug is a partial agonist of α-adrenergic receptors, with considerably reduced potency and efficacy compared to LEK-8842.[1] Due to this action, LEK-8822 can produce vasoconstriction.[1] In addition to its α-adrenergic receptor activity, LEK-8822 shows preserved affinity for but elimination of agonist activity at serotonin 5-HT2 receptors compared to LEK-8842.[1] LEK-8822 was first described in the scientific literature by 1992.[1] It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals.[1]

See also

References

  1. ^ a b c d e f g Krisch I, Budihna MV, Rucman R (1992). "Structure-activity study of some newly synthesized ergoline derivatives on 5-HT2 receptors and alpha-adrenoceptors in rabbit isolated aorta". Pharmacology. 45 (4): 195–208. doi:10.1159/000138998. PMID 1332086.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.